BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm and for Peyronie's disease in men with a palpable plaque and a curvature of 30 degrees or greater at the start of therapy by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium). Auxilium is partnered with Actelion Pharmaceuticals Ltd. for the marketing of XIAFLEX® in Canada, Australia, Mexico and Brazil, and Asahi Kasei Pharma Corporation in Japan for the marketing of XIAFLEX®, and Swedish Orphan Biovitrum AB for the marketing of XIAPEX® (the EU trade name for CCH) in 71 Eurasian and African countries for the treatment of Dupuytren's contracture and Peyronie's disease, pending applicable regulatory approvals.

Patient Discussion Forums

Forums are designed to enable patients and others concerned to interact with each other. Discussions on virtually any aspect of lipoma and Peyronie's disease are acceptable, however, please abide by the guidelines.